Neuronetics, Inc. has taken a significant step in its growth strategy by entering into an underwriting agreement to issue and sell 18,750,000 shares of its common stock at a public offering price of $1.60 per share. This move, announced in a recent SEC filing, is expected to raise approximately $27.7 million, with the potential for an additional $4.2 million if underwriters exercise their option to purchase more shares. The offering is set to close on November 12, 2026, pending customary closing conditions.

The funds raised will be utilized for various purposes, including repaying a portion of outstanding term loans under its credit agreement with Perceptive Credit Holdings IV, LP, and for general corporate needs such as sales and marketing, research and development, and potential acquisitions. Neuronetics currently has $65 million in aggregate principal amount outstanding under this credit facility, which matures in July 2029.

Background

Neuronetics, Inc., incorporated in Delaware, operates within the surgical and medical instruments and apparatus sector (SIC: 3841). The company is publicly traded on the Nasdaq under the ticker symbol STIM. Neuronetics specializes in developing innovative therapies for neurological conditions, primarily through its NeuroStar Advanced Therapy System.

What the Filing Says

According to the SEC filing (accession number 0001193125-26-457099), the company stated, “The Company estimates that the net proceeds to the Company from the Offering...will be approximately $27.7 million.” The filing further details that the offering is being made pursuant to a prospectus supplement dated November 10, 2026.

Impact

This offering may significantly affect Neuronetics' operational capabilities and financial health, allowing for improved cash flow management and debt reduction. Competitors in the surgical and medical instruments market may also feel the pressure as Neuronetics enhances its market position and expands its service offerings.

What's Next

The filing does not specify what happens next, but the anticipated closing of the offering is set for November 12, 2026, subject to customary closing conditions.